Blocking Mineralocorticoid Receptor With Spironolactone May Have a Wide Range of Therapeutic Actions in Severe COVID-19 Disease

Crit Care. 2020 Jun 8;24(1):318. doi: 10.1186/s13054-020-03055-6.

MeSH terms

  • Coronavirus Infections / drug therapy*
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Severity of Illness Index
  • Spironolactone / therapeutic use*

Substances

  • Mineralocorticoid Receptor Antagonists
  • Spironolactone

Supplementary concepts

  • COVID-19